The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations-Reference-Cited by-同舟云学术

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

Published:2022-08-30 Issue:10 Volume:31 Page:1637-1646
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Joyce Ryan P.,Hu Vivian W.,Wang Jun^ORCID

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-022-02951-6.pdf

Reference47 articles.

1. Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants Comment. Cell. 2021;184:1127–32. https://doi.org/10.1016/j.cell.2021.01.044.

2. Johns Hopkins Coronavirus Resource Center. 2022. https://coronavirus-jhu-edu.proxy.libraries.rutgers.edu/map.html.

3. Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, El-Ella DMA, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54:524–40. https://doi.org/10.1080/07853890.2022.2031274.

4. Kontoghiorghes GJ, Fetta S, Kontoghiorghe CN. The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic. Front Biosci. 2021;26:1723–36. https://doi.org/10.52586/5064.

5. Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, et al. Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs. Antimicrob Agents Chemother. 2021;65. https://doi.org/10.1128/aac.01155-21.

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Nirmatrelvir (Paxlovid with Ritonavir): A 3‐Chymotrypsin‐like Protease Inhibitor for Treating SARS‐CoV‐2 Infection;Chemistry and Pharmacology of Drug Discovery;2024-08-16

3. Predicting Clinical Outcomes of SARS‐CoV‐2 Drug Efficacy with a High‐Throughput Human Airway Microphysiological System;Advanced Biology;2024-08-09

4. Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors;Viruses;2024-07-29

5. Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling;Viruses;2024-07-18